Skinvisible, Inc. operates via a patented polymer technology aimed at enhancing topical drug delivery, licensing its formulations globally to pharmaceutical and consumer companies. Despite completing R&D on over forty products and securing multiple patents, the company has yet to generate significant revenues, posting consistent losses and a substantial accumulated deficit. Future growth hinges on clinical progress by licensees such as Quoin Pharmaceuticals along with successful capital raises to sustain operations. The firm faces risks from its limited resources, dependency on license-generated income, regulatory complexities, and competitive dynamics in the skincare and pharmaceutical arenas.